In 2006, IAVI and its Neutralizing Antibody Consortium launched the Protocol G project to search for bNAbs against HIV, partnering with clinical research centers in Africa, India, Thailand, Australia, the United Kingdom, and the United States. More than 1,800 healthy, HIV-positive volunteers contributed blood samples to be screened. In 2009, scientists from IAVI, The Scripps Research Institute, and Theraclone Sciences collaborated to isolate and characterize the first new bNAbs to HIV seen in a decade and the first to be isolated from donors in developing countries, where the majority of new HIV infections occur. To date, more than 25 new bNAbs have been isolated and characterized from Protocol G specimens, and many have been shared with researchers across the AIDS vaccine field.
Protocol G
A cross sectional study to assess HIV-neutralizing antibody activity among persons living with HIV between 2007 and 2012
In 2006, IAVI and its Neutralizing Antibody Consortium launched the Protocol G project to search for bNAbs against HIV, partnering with clinical research centers in Africa, India, Thailand, Australia, the United Kingdom, and the United States. More than 1,800 healthy, HIV-positive volunteers contributed blood samples to be screened. In 2009, scientists from IAVI, The Scripps Research Institute, and Theraclone Sciences collaborated to isolate and characterize the first new bNAbs to HIV seen in a decade and the first to be isolated from donors in developing countries, where the majority of new HIV infections occur. To date, more than 25 new bNAbs have been isolated and characterized from Protocol G specimens, and many have been shared with researchers across the AIDS vaccine field.
Type: Prevalence / cross-sectional
Study Status: Closed
Enrollment Status: Closed
Countries: Australia, India, Ivory Coast, Kenya, Nigeria, Rwanda, South Africa, Thailand, Uganda, United Kingdom, United States, Zambia
Study Summary
To generate broadly neutralizing monoclonal antibodies (mAbs) from volunteers who are HIV infected and have broadly cross-reactive serum neutralizing activity.
Partners: Uganda Virus Research Institute-International AIDS Vaccine Initiative (UVRI-IAVI), Entebbe, Uganda;Zambia-Emory Research Project (ZEHRP), Lusaka, Zambia;Projet San Francisco (PSF-Kigali), Kigali, Rwanda;Kenya AIDS Vaccine Initiative-Kenyatta National Hospital (KAVI-KNH), Nairobi, Kenya;YRG Care, Chennai, India;Vaccine Trial Centre, Mahidol University, Bangkok, Thailand;Centre de Diagnostic et de Recherche sur le SIDA et les infections opportunistes (CeDReS), CHU Treichville, Abidjan, Côte d’Ivoire;Institute of Human Virology (IHV), Nigeria;National Serology Reference Laboratory (NRL), Australia;St. Stephen’s Centre, London, UK;SUNY Downstate Medical Center, New York, USA;AFRIMS (Armed Forces Research Institute of Medical Sciences), Bangkok, Thailand